Sanofi's Merial wins EU approval for chewable anti-parasitic; Virbac sees strong 2014 sales growth in emerging countries;

> The European Commission has approved NexGard Spectra, a beef-flavored chew to prevent parasites in dogs that's made by Sanofi's ($SNY) animal health unit, Merial. Release

> France's Virbac announced that its 2014 sales grew 5% year-over-year to €773.2 million ($896 million), with double-digit growth in emerging countries such as Mexico, India and South Africa. Release

> Henry Schein ($HSIC) will acquire scil animal care company GmbH, a distributor of laboratory and imaging products to animal health providers. Release

> Generic pet drug maker Putney received its fifth FDA approval in five months, for a generic version of Bayer's injectable antibacterial medicine Baytril. Release

> A study partially funded by Zoetis ($ZTS) and the Pfizer ($PFE) Foundation suggests that therapy dogs can significantly improve the emotional well being of some cancer patients. Release

> Veterinary hospital chain VCA ($WOOF) has named Trupanion ($TRUP) as its preferred vendor for pet insurance. Release

> In a study that may be relevant to injury research in people, scientists at North Carolina State University showed that a combination of two experimental drugs helped improve the mobility of some paralyzed dogs. Article

> Connecticut-based Oma's Pride has recalled its Purr-Complete Feline Poultry Meal due to possible Salmonella contamination. Release

> Abaxis ($ABAX) won USDA approval of its VetScan FeLV/FIV Feline Rapid Test. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…